These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11698916)

  • 1. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL; Burkland GA
    MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM; Kovacs MJ
    Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are various Babesia species a missed cause for hypereosinophilia? A follow-up on the first reported case of imatinib mesylate for idiopathic hypereosinophilia.
    Schaller JL; Burkland GA; Langhoff PJ
    MedGenMed; 2007 Feb; 9(1):38. PubMed ID: 17435644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL; Larsen H
    Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
    Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reader's response to "Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate".
    Shinkarow JW
    MedGenMed; 2007; 9(1):39. PubMed ID: 17441290
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement.
    Anghel G; De Rosa L; Ruscio C; Petti N; Riccardi M; Severino A; Majolino I
    Tumori; 2005; 91(1):67-70. PubMed ID: 15850007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
    Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
    Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
    Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
    Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
    Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
    Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
    [No Abstract]   [Full Text] [Related]  

  • 20. [Practical approach to hypereosinophilia].
    Roufosse F; Cogan E
    Rev Med Brux; 2008 Sep; 29(4):400-8. PubMed ID: 18949995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.